124 related articles for article (PubMed ID: 22123213)
1. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.
Wimazal F; Geissler P; Shnawa P; Sperr WR; Valent P
Int Arch Allergy Immunol; 2012; 157(4):399-405. PubMed ID: 22123213
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience.
Gülen T; Hägglund H; Dahlén B; Nilsson G
Clin Exp Allergy; 2014 Jan; 44(1):121-9. PubMed ID: 24164252
[TBL] [Abstract][Full Text] [Related]
3. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Hennessy B; Giles F; Cortes J; O'brien S; Ferrajoli A; Ossa G; Garcia-Manero G; Faderl S; Kantarjian H; Verstovsek S
Am J Hematol; 2004 Nov; 77(3):209-14. PubMed ID: 15495258
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
6. Cladribine therapy for systemic mastocytosis.
Kluin-Nelemans HC; Oldhoff JM; Van Doormaal JJ; Van 't Wout JW; Verhoef G; Gerrits WB; van Dobbenburgh OA; Pasmans SG; Fijnheer R
Blood; 2003 Dec; 102(13):4270-6. PubMed ID: 12933573
[TBL] [Abstract][Full Text] [Related]
7. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.
Aichberger KJ; Sperr WR; Gleixner KV; Kretschmer A; Valent P
Eur J Clin Invest; 2008 Nov; 38(11):869-73. PubMed ID: 19021706
[TBL] [Abstract][Full Text] [Related]
8. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases.
Tefferi A; Kittur J; Farrukh F; Begna KH; Patnaik MM; Al-Kali A; Elliott MA; Reichard KK; Gangat N; Pardanani A
Br J Haematol; 2022 Feb; 196(4):975-983. PubMed ID: 34729775
[TBL] [Abstract][Full Text] [Related]
9. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.
Brockow K; Jofer C; Behrendt H; Ring J
Allergy; 2008 Feb; 63(2):226-32. PubMed ID: 18186813
[TBL] [Abstract][Full Text] [Related]
10. Systemic mastocytosis: current concepts and treatment advances.
Tefferi A; Pardanani A
Curr Hematol Rep; 2004 May; 3(3):197-202. PubMed ID: 15087068
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases.
Matito A; Álvarez-Twose I; Morgado JM; Sánchez-Muñoz L; Orfao A; Escribano L
Int Arch Allergy Immunol; 2011; 156(1):104-11. PubMed ID: 21447966
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase.
Potier A; Lavigne C; Chappard D; Verret JL; Chevailler A; Nicolie B; Drouet M
Clin Exp Allergy; 2009 May; 39(5):717-25. PubMed ID: 19302252
[TBL] [Abstract][Full Text] [Related]
14. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders.
Valent P
Clin Exp Allergy; 2014 Jul; 44(7):914-20. PubMed ID: 24702655
[TBL] [Abstract][Full Text] [Related]
17. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.
Pardanani A; Tefferi A
Curr Opin Hematol; 2010 Mar; 17(2):125-32. PubMed ID: 20075725
[TBL] [Abstract][Full Text] [Related]
18. Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a pediatric patient: case report and literature review.
Shaffer HC; Parsons DJ; Peden DB; Morrell D
J Am Acad Dermatol; 2006 May; 54(5 Suppl):S210-3. PubMed ID: 16631942
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Gruson B; Lortholary O; Canioni D; Chandesris O; Lanternier F; Bruneau J; Grosbois B; Livideanu C; Larroche C; Durieu I; Barete S; Sevestre H; Diouf M; Chaby G; Marolleau JP; Dubreuil P; Hermine O; Damaj G
Br J Haematol; 2013 May; 161(3):434-42. PubMed ID: 23432617
[TBL] [Abstract][Full Text] [Related]
20. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.
Bonadonna P; Perbellini O; Passalacqua G; Caruso B; Colarossi S; Dal Fior D; Castellani L; Bonetto C; Frattini F; Dama A; Martinelli G; Chilosi M; Senna G; Pizzolo G; Zanotti R
J Allergy Clin Immunol; 2009 Mar; 123(3):680-6. PubMed ID: 19135713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
